Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Deere & Company (DE) vs GeneDx Holdings Corp (WGS) Price & Performance

Deere & CompanyTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Deere & Company vs GeneDx Holdings Corp — how do they compare? Deere & Company trades at $652.58 (market cap $177.11B), while GeneDx Holdings Corp trades at $67.67 (market cap $2.04B). The key difference: Deere & Company is far larger — about 86.8× GeneDx Holdings Corp's market cap, and Deere & Company pays a 0.99% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deere & Company for 75 Days and GeneDx Holdings Corp for 19 Days on average.

DEWGS
Market Cap
$177.11B$2.04B
Volume
1,206,308659,215
Sector
IndustrialsHealth
52-Week High
$709.48$167.51
52-Week Low
$439.11$34.51
Typical Hold Time
75 Days19 Days
Enterprise Value
$231.01B$2.08B
Dividend Yield
0.99%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Deere & Company

Deere & Company (DE) trades at $652.58, down 4.42% today, showing bearish technical signals with support at $643 and resistance at $658. The company maintains strong profitability with a 10.39% net margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights Deere's AI initiatives and institutional buying interest, though revenue has declined from 2023 peaks.

Deere presents a mixed outlook with solid fundamentals and analyst support (43.48% buy rating, $731.20 target) but faces agricultural cycle headwinds and competitive pressures. The stock offers potential upside from AI-driven farming solutions but risks include cyclical demand volatility and high debt levels at 60.31% of assets.

GeneDx Holdings Corp

GeneDx (WGS) trades at $68.53, down 4.18% today amid bearish technical signals despite recent positive earnings surprises. The stock shows mixed fundamentals with strong revenue growth to $454M in 2026 but negative profitability metrics including -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target representing 18% upside potential.

The investment case balances strong analyst support and genomic testing market growth against persistent profitability challenges and negative cash flow trends. Key catalysts include Q3 2026 earnings due soon and continued execution on operational improvements, while risks center on margin recovery timeline and competitive pressures in the rapidly evolving genomics space.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DE
100% Buy0% Sell
Avg holding period · 75 Days
WGS
53% Buy47% Sell
Avg holding period · 19 Days

Top news

Latest headlines on both assets

About Deere & Company

Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.

Read more on DE →

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS →